Related Experiment Video
Updated: Jun 28, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
[Immunotherapy using IL-6 receptor as the target].
1Laboratory of Immune Regulation, Wakayama Medical University.
Summary
Monoclonal antibody therapy targeting interleukin-6 (IL-6) effectively treats autoimmune and inflammatory diseases. Tocilizumab, an IL-6 receptor inhibitor, shows robust safety and efficacy in clinical trials for various conditions.
Area of Science:
- Immunotherapy
- Cytokine Signaling
- Autoimmune Disease Treatment
Background:
- Interleukin-6 (IL-6) is a key cytokine implicated in the pathology of autoimmune diseases, chronic inflammatory conditions, and lymphoproliferative disorders.
- IL-6 plays a significant role in diseases such as Castleman's disease, rheumatoid arthritis, juvenile idiopathic arthritis, and Crohn's disease.
- Blocking the IL-6 signaling pathway is a recognized therapeutic strategy.
Purpose of the Study:
- To review the therapeutic approach of targeting interleukin-6 (IL-6) actions as an immunotherapy.
- To discuss the role of tocilizumab, a monoclonal antibody targeting the IL-6 receptor, in clinical applications.
Main Methods:
- Review of existing literature and clinical trial data on IL-6 targeted therapies.
- Focus on tocilizumab as a representative humanized monoclonal antibody against the human IL-6 receptor.
Main Results:
- Tocilizumab has been extensively studied in clinical trials.
- Clinical trials have demonstrated the safety and efficacy of tocilizumab in treating patients with IL-6-mediated diseases.
- Targeting IL-6 actions represents a viable immunotherapy approach.
Conclusions:
- Monoclonal antibody therapy targeting IL-6, exemplified by tocilizumab, is an established and effective treatment modality.
- The safety and efficacy profile of tocilizumab supports its use in managing autoimmune and inflammatory conditions.
- Targeting IL-6 signaling is a crucial immunotherapy strategy for various debilitating diseases.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...